Manufacturing, Inhalation Drugs

Breathing Easier

November 02, 2023

A novel approach for safety assessments in inhalation drugs may avoid animal testing for drug products.

Stevanato Group and Recipharm to Collaborate on Pre-fillable Syringes for Soft Mist Inhaler

March 17, 2023

Stevanato Group will support development and production of pre-fillable syringes for use in Recipharm’s soft mist inhalers.

Lonza Joins IPAC-RS, an International Consortium Advancing the Regulatory Science of Inhalation Products

April 05, 2022

Lonza has joined IPAC-RS, providing benefits to Lonza’s inhalation- related businesses due to IPAC-RS’ global voice of the orally inhaled and nasal drug products industry.

Spray Drying Finds Growing Use for ASDs

February 01, 2022

CDMOs offer expertise and capacity for spray drying.

Considerations for DPIs and MDIs in Inhalation Drug Delivery

October 15, 2021

Experts share best practices in designing, manufacturing, and scaling up dry powder inhaler and metered dose inhaler drug–device combination products for inhalation drug delivery.

Best Practices in Manufacturing Inhalation Drugs

September 13, 2021

When designing and manufacturing a pMDI or DPI combination drug-delivery device, the commercial stage should be kept in mind from the beginning of development.

FDA Grants Orphan Drug Designation to Aerami Therapeutics’s Imatinib

August 27, 2021

FDA granted orphan drug designation for imatinib in AER-901 for the treatment of patients with pulmonary arterial hypertension.

Integrated Approach Facilitates Inhalation Drug Development

August 01, 2021

The choice of delivery platform for inhaled drug products is contingent on API-related factors, as well as the development stage of the product.

Spray Drying as an Enabling Technology for Inhalation Drug Delivery

July 03, 2021

Particle performance in a DPI can be optimized by fine-tuning the formulation and manufacturing process parameters.

Vectura Partners with Cannabinoid Medicines Company

July 01, 2021

Vectura will provide preclinical development services for Incannex’s inhaled drug product for the treatment of traumatic brain injury.